These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20505339)

  • 1. Turning off the switch in medulloblastoma: the inhibitory acetylation of an oncogene.
    Canettieri G; Di Marcotullio L; Coni S; Greco A; Gulino A
    Cell Cycle; 2010 Jun; 9(11):2047-8. PubMed ID: 20505339
    [No Abstract]   [Full Text] [Related]  

  • 2. Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation.
    Canettieri G; Di Marcotullio L; Greco A; Coni S; Antonucci L; Infante P; Pietrosanti L; De Smaele E; Ferretti E; Miele E; Pelloni M; De Simone G; Pedone EM; Gallinari P; Giorgi A; Steinkühler C; Vitagliano L; Pedone C; Schinin ME; Screpanti I; Gulino A
    Nat Cell Biol; 2010 Feb; 12(2):132-42. PubMed ID: 20081843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medulloblastoma: a problem of developmental biology.
    Rubin JB; Rowitch DH
    Cancer Cell; 2002 Jul; 2(1):7-8. PubMed ID: 12150819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hedgehog drugs begin to show results.
    Garber K
    J Natl Cancer Inst; 2008 May; 100(10):692-7. PubMed ID: 18477794
    [No Abstract]   [Full Text] [Related]  

  • 5. REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma.
    Di Marcotullio L; Ferretti E; De Smaele E; Argenti B; Mincione C; Zazzeroni F; Gallo R; Masuelli L; Napolitano M; Maroder M; Modesti A; Giangaspero F; Screpanti I; Alesse E; Gulino A
    Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10833-8. PubMed ID: 15249678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors: a review on class-I specific inhibition.
    Behera J; Jayaprakash V; Sinha BN
    Mini Rev Med Chem; 2015; 15(9):731-50. PubMed ID: 25994050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hitting the target in medulloblastoma therapy.
    Bradbury J
    Drug Discov Today; 2004 Dec; 9(23):994-5. PubMed ID: 15574311
    [No Abstract]   [Full Text] [Related]  

  • 8. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDACs and MYC in medulloblastoma: how do HDAC inhibitors control MYC-amplified tumors?
    Shofuda T; Kanemura Y
    Neuro Oncol; 2021 Feb; 23(2):173-174. PubMed ID: 33394043
    [No Abstract]   [Full Text] [Related]  

  • 10. Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma.
    Mascaro-Cordeiro B; Oliveira ID; Tesser-Gamba F; Pavon LF; Saba-Silva N; Cavalheiro S; Dastoli P; Toledo SRC
    Childs Nerv Syst; 2018 Aug; 34(8):1497-1509. PubMed ID: 29785653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity.
    Falkenberg KJ; Newbold A; Gould CM; Luu J; Trapani JA; Matthews GM; Simpson KJ; Johnstone RW
    Cell Death Differ; 2016 Jul; 23(7):1209-18. PubMed ID: 26868908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic potential of modulators of the Hedgehog-Gli signaling pathway.
    Stecca B; Ruiz i Altaba A
    J Biol; 2002 Nov; 1(2):9. PubMed ID: 12437768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC inhibitors to the rescue in sonic hedgehog medulloblastoma.
    Becher OJ
    Neuro Oncol; 2019 Sep; 21(9):1091-1092. PubMed ID: 31242287
    [No Abstract]   [Full Text] [Related]  

  • 14. The hedgehog pathway and neurological disorders.
    Dellovade T; Romer JT; Curran T; Rubin LL
    Annu Rev Neurosci; 2006; 29():539-63. PubMed ID: 16776596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
    Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
    Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
    Dijkgraaf GJ; Alicke B; Weinmann L; Januario T; West K; Modrusan Z; Burdick D; Goldsmith R; Robarge K; Sutherlin D; Scales SJ; Gould SE; Yauch RL; de Sauvage FJ
    Cancer Res; 2011 Jan; 71(2):435-44. PubMed ID: 21123452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
    Giannini G; Battistuzzi G; Vignola D
    Bioorg Med Chem Lett; 2015 Feb; 25(3):459-61. PubMed ID: 25563890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone H4 HDAC activity is necessary for expression of the PU.1 gene.
    Laribee RN; Klemsz MJ
    Biochim Biophys Acta; 2005 Sep; 1730(3):226-34. PubMed ID: 16139904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of Acetylation of the Gli Transcription Factors.
    Coni S; Di Magno L; Canettieri G
    Methods Mol Biol; 2015; 1322():147-56. PubMed ID: 26179046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vorinostat approved for rare lymphoma.
    Thompson CA
    Am J Health Syst Pharm; 2006 Nov; 63(22):2168. PubMed ID: 17090730
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.